Pharma Partnerships Leverage existing pharma interest, including Merck investment and Yale collaboration, to offer ctDNA-guided trial design support, MRD-based patient stratification, and companion diagnostic development to accelerate oncology drug programs.

MRD Across Cancers Position ultrasensitive MRD and ctDNA monitoring as a versatile endpoint across multiple tumor types, appealing to CROs and biopharma for monitoring response and relapse in clinical trials and post-market surveillance.

Academic Collaborations Expand partnerships with leading cancer centers (Yale, ICR, Royal Marsden) to co-develop and validate new genomic panels, offering access to Personalis' profiling and analytics as a research service or companion diagnostic development.

Clinical Trial Enablement Offer end-to-end trial support: design, sample processing, sequencing, analytics, and reporting for ctDNA-guided therapies, with SOC 2 compliant workflows and integrations that fit enterprise LIMS/EMR environments.

Scale Opportunities With steady funding and strategic investors, present opportunities to expand sequencing throughput, add biomarkers, and integrate with pharma pipelines, enabling longer-term multi-year agreements and bundled services.